Apertura Gene Therapy

Apertura Gene Therapy develops next-generation AAV-based gene therapies by simultaneously engineering viral capsids, genetic regulatory elements, and therapeutic payloads. Their proprietary platforms address key limitations in current gene therapy approaches such as cellular access, immune evasion, manufacturability, and precise control of transgene expression. The company’s lead internal programs target CNS disorders using engineered AAVs that cross the blood-brain barrier via human TfR1 targeting. They also collaborate with leading academic groups on innovative approaches like epigenetic silencing for prion disease. No clinical results have been reported yet; the pipeline remains preclinical with an IND planned soon.